<DOC>
	<DOC>NCT02526420</DOC>
	<brief_summary>A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.</brief_summary>
	<brief_title>Versartis International Trial in Adults With Long-Acting Growth Hormone</brief_title>
	<detailed_description>A Phase 2, dose finding safety study to evaluate an individualized monthly VRS-317 dosing regimen in adults with GHD. This is an open-label, international, multicenter study with VRS-317 treatment for five months. This treatment period will include monthly dose titrations until a subject's mean IGF-I SDS value is within a target range for two consecutive months. Subjects will be stratified into three cohorts based on sensitivity to rhGH.</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Female subjects of childbearing potential must have negative pregnancy test and use appropriate contraceptive methods Subjects must have documented GHD during adulthood. Subjects taking other hormone replacement therapy must have been on a stable course of treatment for at least 3 months. Subjects with underlying disorders responsible for the subject's GHD must have been clinically stable for at least 6 months. Subjects receiving daily rhGH injections must washout for 14 days. Subjects must provide signed informed consent. Subjects must have a BMI (kg/m2) between 19.0 and 35.0. Subjects with diabetes mellitus or inadequate glucose control Subjects with untreated adrenal insufficiency. Subjects with free thyroxine outside the normal reference range. Subjects currently taking oral glucocorticoids, except for physiological maintenance doses of oral glucocorticoids in subjects with multiple pituitary hormone deficiencies. Subjects with current significant cardiovascular disease, heart insufficiency of NYHA class &gt; 2. Subjects with current significant cerebrovascular, pulmonary, neurological, renal, inflammatory, or hepatobiliary disease. Subjects with current papilledema. Subjects with a history of persistent or recurring migraines. Subjects with current edema (â‰¥ CTCAE Grade 2). Subjects with current drug or alcohol abuse. Subjects with a documented history of HIV, current HBV or HCV infection Subjects with a prior history of malignancy excluding adequately treated nonmelanoma skin cancers or in situ carcinoma of the cervix. Women who are pregnant or breastfeeding. Subjects with a significant abnormality in Screening laboratory results</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>VRS-317</keyword>
	<keyword>Long Acting Growth Hormone</keyword>
	<keyword>Versartis</keyword>
	<keyword>somavaratan</keyword>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Adult Growth Hormone Deficiency</keyword>
	<keyword>AGHD</keyword>
	<keyword>Growth Hormone Replacement</keyword>
	<keyword>Growth Hormone Replacement Therapy</keyword>
	<keyword>XTEN</keyword>
</DOC>